

ASX Announcement

10 March 2021

Cogstate Limited
ABN 80 090 975 723

Suite 117
425 Smith Street
Fitzroy Victoria 3065
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

Notification of Change of Director's Interests

Cogstate (ASX:CGS) has announced that Cogstate CEO, Mr Brad O'Connor has sold 2,250,000 Cogstate Ltd ordinary shares at \$0.90 per share, raising total sale proceeds of A\$2,013,862.50 after costs.

The sale of Cogstate shares was undertaken in order to fund personal financial obligations, including:

- Settlement funds in respect of the purchase of personal residence;
- Tax obligations related to the taxation of options exercised under the Cogstate Ltd Employee Share Option Plan; and
- The exercise of Cogstate Ltd share options under the Cogstate Employee Share Option Plan.

Upon settlement of the sale proceeds and then exercise of the employee options, the appropriate disclosure notices will be lodged with the ASX.

Following the share sale announced today, Mr O'Connor (and associates) have no intention of making further sale of Cogstate Ltd shares until 2022 calendar year, at which time a further share sale is expected in order to fund the exercise of Cogstate Ltd employee options that will be due around that time.

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com